ES2606906T3 - Métodos para inhibir la unión de la endosialina a ligandos - Google Patents

Métodos para inhibir la unión de la endosialina a ligandos Download PDF

Info

Publication number
ES2606906T3
ES2606906T3 ES13162773.9T ES13162773T ES2606906T3 ES 2606906 T3 ES2606906 T3 ES 2606906T3 ES 13162773 T ES13162773 T ES 13162773T ES 2606906 T3 ES2606906 T3 ES 2606906T3
Authority
ES
Spain
Prior art keywords
endosialin
cells
cell
expression
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13162773.9T
Other languages
English (en)
Spanish (es)
Inventor
Yuhong Zhou
Brian E. Tomkowicz
Luigi Grasso
Philip M. Sass
Nicolas C. Nicolaides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphotek Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Application granted granted Critical
Publication of ES2606906T3 publication Critical patent/ES2606906T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES13162773.9T 2007-04-05 2008-04-04 Métodos para inhibir la unión de la endosialina a ligandos Active ES2606906T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US910362P 2007-04-05
US98002607P 2007-10-15 2007-10-15
US980026P 2007-10-15

Publications (1)

Publication Number Publication Date
ES2606906T3 true ES2606906T3 (es) 2017-03-28

Family

ID=39714208

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13162773.9T Active ES2606906T3 (es) 2007-04-05 2008-04-04 Métodos para inhibir la unión de la endosialina a ligandos
ES08733125.2T Active ES2452929T3 (es) 2007-04-05 2008-04-04 Métodos para inhibir la unión de endosialina a ligandos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08733125.2T Active ES2452929T3 (es) 2007-04-05 2008-04-04 Métodos para inhibir la unión de endosialina a ligandos

Country Status (20)

Country Link
US (4) US7807382B2 (enExample)
EP (2) EP2620451B1 (enExample)
JP (2) JP5825784B2 (enExample)
KR (1) KR101529334B1 (enExample)
CN (1) CN101918446B (enExample)
AU (1) AU2008237296B2 (enExample)
BR (1) BRPI0809665B8 (enExample)
CA (1) CA2682726C (enExample)
CY (2) CY1115370T1 (enExample)
DK (2) DK2620451T3 (enExample)
ES (2) ES2606906T3 (enExample)
HR (2) HRP20140266T1 (enExample)
HU (1) HUE031269T2 (enExample)
LT (1) LT2620451T (enExample)
MX (1) MX2009010701A (enExample)
PL (2) PL2620451T3 (enExample)
PT (2) PT2137217E (enExample)
RS (2) RS53362B (enExample)
SI (2) SI2137217T1 (enExample)
WO (1) WO2008124570A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241235B2 (en) * 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
EP2620451B1 (en) 2007-04-05 2016-09-14 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
WO2012050883A1 (en) 2010-09-29 2012-04-19 Morphotek, Inc. Engineered human endosialin-expressing rodents
JP6285414B2 (ja) 2012-03-30 2018-02-28 モルフォテック， インコーポレイテッド Ｔｅｍ−１診断用抗体
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
HK1219980A1 (zh) 2013-03-09 2017-04-21 Baylor College Of Medicine 靶向血管的t细胞疗法
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2020254610A1 (en) 2019-04-01 2021-11-18 Applied Therapeutics Inc. Inhibitors of aldose reductase
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
US5545532A (en) 1993-02-05 1996-08-13 Epigen, Inc. Human carcinoma antigen (HCA), HCA antibodies, HCA immunoassays and methods of imaging
WO1995024483A1 (en) * 1994-03-08 1995-09-14 Scotgen Biopharmaceuticals, Inc. Recombinant humanized anti-fb5 antibodies
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
US6263223B1 (en) 1998-09-09 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Method for monitoring arterial oxygen saturation
WO2001068912A2 (en) 2000-03-15 2001-09-20 Epigenomics Ag Diagnosis of diseases associated with tumor suppressor genes and oncogenes
EP1307557A2 (en) 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
DE60144247D1 (de) 2001-01-15 2011-04-28 Morphotek Inc Chemische hemmstoffe des mismatch-repair
US20040043928A1 (en) 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
EP1576131A4 (en) 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
KR20060003860A (ko) 2003-03-04 2006-01-11 기린 비루 가부시키가이샤 내피 세포 특이적 항체 및 그의 용도
WO2005086713A2 (en) 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
JP2008513533A (ja) 2004-09-23 2008-05-01 ゲルベ Ｃｅｓｔイメージング用の造影剤封入システム
WO2006060719A2 (en) 2004-12-03 2006-06-08 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
AU2006241235B2 (en) 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
CA2633593A1 (en) 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
WO2008006517A2 (en) 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
WO2008009132A1 (en) 2006-07-21 2008-01-24 The Governors Of The University Of Alberta Tissue rejection
EP2949763A3 (en) 2006-08-11 2016-03-09 Johns Hopkins University Consensus coding sequences of human breast cancers
US20080300170A1 (en) 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
EP2620451B1 (en) 2007-04-05 2016-09-14 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
EP2696203A3 (en) 2007-08-16 2014-05-28 The Royal Institution for the Advancement of Learning/McGill University Tumor cell-derived microvesicles
ES2936256T3 (es) 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
EP2250287B1 (en) 2008-02-19 2013-09-18 MDxHealth SA Detection and prognosis of lung cancer
WO2009120877A2 (en) 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
WO2010083252A2 (en) 2009-01-14 2010-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
WO2010118203A2 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Also Published As

Publication number Publication date
CA2682726A1 (en) 2008-10-16
DK2620451T3 (da) 2017-01-02
US20110033455A1 (en) 2011-02-10
EP2137217A1 (en) 2009-12-30
RS55447B1 (sr) 2017-04-28
PL2137217T3 (pl) 2014-08-29
ES2452929T3 (es) 2014-04-03
HRP20161715T1 (hr) 2017-02-10
BRPI0809665A2 (en) 2018-12-04
CN101918446A (zh) 2010-12-15
US9505842B2 (en) 2016-11-29
AU2008237296A1 (en) 2008-10-16
DK2137217T3 (en) 2014-03-17
JP5825784B2 (ja) 2015-12-02
US20150079104A1 (en) 2015-03-19
CN101918446B (zh) 2014-06-18
KR20100016221A (ko) 2010-02-12
JP2010523592A (ja) 2010-07-15
PL2620451T3 (pl) 2017-06-30
US20080248034A1 (en) 2008-10-09
US20170029509A1 (en) 2017-02-02
EP2620451A1 (en) 2013-07-31
WO2008124570A8 (en) 2008-11-27
SI2620451T1 (sl) 2017-01-31
SI2137217T1 (sl) 2014-07-31
CY1115370T1 (el) 2017-01-04
PT2620451T (pt) 2016-12-20
JP2013150618A (ja) 2013-08-08
BRPI0809665B8 (pt) 2021-05-25
EP2620451B1 (en) 2016-09-14
AU2008237296B2 (en) 2013-07-04
RS53362B (sr) 2014-10-31
CA2682726C (en) 2017-05-09
EP2137217B1 (en) 2014-03-05
HUE031269T2 (en) 2017-06-28
US7807382B2 (en) 2010-10-05
MX2009010701A (es) 2010-01-20
US8895000B2 (en) 2014-11-25
PT2137217E (pt) 2014-03-20
LT2620451T (lt) 2017-01-10
KR101529334B1 (ko) 2015-06-16
US10053509B2 (en) 2018-08-21
WO2008124570A1 (en) 2008-10-16
CY1118592T1 (el) 2017-07-12
HRP20140266T1 (hr) 2014-04-25
BRPI0809665B1 (pt) 2021-03-23

Similar Documents

Publication Publication Date Title
ES2452929T3 (es) Métodos para inhibir la unión de endosialina a ligandos
US10260068B2 (en) Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
Orlandini et al. The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target
CN101189264A (zh) M-csf特异性单克隆抗体及其应用
US9790503B2 (en) VHZ for diagnosis and treatment of cancer
JP5756014B2 (ja) がんの診断および治療のためのｖｈｚ
CN109072236A (zh) 用于生产分泌蛋白质的哺乳动物细胞
JPWO2007018316A1 (ja) 癌の予防・治療剤
ES2673518T3 (es) Métodos para modificar las tasas de producción de proteínas
JP5427348B2 (ja) エフェクター機能が向上した抗体
US20070224194A1 (en) Methods for Inhibiting Angiogenesis and/or Lymphangiogenesis
WO2006093337A1 (ja) 癌の予防・治療剤
WO2007020965A1 (ja) 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
JP6973736B2 (ja) 生理活性タンパク質の同定方法及びその方法によって得られた生理活性タンパク質
US20080066196A1 (en) Short interfering rna duplexes targeting an ires sequence and uses therefor